0

Lupin Ltd (LUPIN) – Financial and Strategic SWOT Analysis Review

Publisher Name :
Date: 20-Apr-2017
No. of pages: 60

Lupin Ltd (LUPIN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Lupin Ltd (Lupin) is transnational pharmaceutical company. It is one of the leading generic pharmaceutical companies across the world. The company focuses on the development and manufacture of generic and branded formulations, biotechnology products and active pharmaceutical ingredients (APIs). The company has expertise in the areas of cardiovascular, asthma, diabetology, pediatrics, central nervous system, anti-infectives, NSAIDs, anti-TB and cephalosporins. The company undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation. It has operations in various countries worldwide including India, the US, the UK, Germany, Japan, South Africa, Philippines, and Australia. Lupin is headquartered in Mumbai, Maharashtra, India.

Lupin Ltd Key Recent Developments

Feb 09,2017: Lupin Quarter III Results, FY2017
Nov 09,2016: Lupin’s Quarter II, FY2017 – Results
Nov 04,2016: Lupin Receives EIR From US FDA for Goa, March 2016 Inspection
Aug 09,2016: Lupin: Record Sales Profits – Quarter I FY2017
Aug 09,2016: Lupin announces first quarter ended June 30, 2016 financila results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of content
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 - About the Company 6
Lupin Ltd - Key Facts 6
Lupin Ltd - Key Employees 7
Lupin Ltd - Key Employee Biographies 8
Lupin Ltd - Major Products and Services 9
Lupin Ltd - Pharmaceutical Pipeline Products Data 10
Lupin Ltd, Pipeline Products by Therapy Area 10
Lupin Ltd, Pipeline Products by Development Phase 12
Lupin Ltd - History 13
Lupin Ltd - Company Statement 19
Lupin Ltd - Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Joint Venture 23
Section 2 - Company Analysis 24
Lupin Ltd - Business Description 24
Lupin Ltd - Corporate Strategy 25
Lupin Ltd - SWOT Analysis 26
SWOT Analysis - Overview 26
Lupin Ltd - Strengths 26
Lupin Ltd - Weaknesses 27
Lupin Ltd - Opportunities 28
Lupin Ltd - Threats 30
Lupin Ltd - Key Competitors 31
Section 3 - Company Financial Ratios 32
Financial Ratios - Capital Market Ratios 32
Financial Ratios - Annual Ratios 33
Performance Chart 36
Financial Performance 36
Financial Ratios - Interim Ratios 37
Financial Ratios - Ratio Charts 38
Section 4 - Company's Lifesciences Financial Deals and Alliances 39
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 39
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 40
Lupin Ltd, Recent Deals Summary 41
Section 5 - Company's Recent Developments 42
Feb 09, 2017: Lupin Quarter III Results, FY2017 42
Nov 09, 2016: Lupin's Quarter II, FY2017 - Results 44
Nov 04, 2016: Lupin Receives EIR From US FDA for Goa, March 2016 Inspection 46
Aug 09, 2016: Lupin: Record Sales Profits - Quarter I FY2017 47
Aug 09, 2016: Lupin announces first quarter ended June 30, 2016 financila results 49
Jul 07, 2016: Lupin receives EIR from US FDA for Goa, July 2015 Inspection 50
Jun 07, 2016: Lupin Appoints Yugesh Goutam as President - Global HR 51
May 26, 2016: Lupin announces closure of US FDA Audits for its Mandideep and Aurangabad Facilities 52
May 19, 2016: Record Sales & Profits - A New High Quarter IV & Annual Results - FY2016 Q4 FY2016 Net Sales up 34.0%, EBITDA up 72.7%, Net profit up 47.5% Proposed Dividend 375% 53
Apr 05, 2016: Lupin Appoints Dr. Kurt Nielsen as President of Lupin - Somerset 55
Section 6 - Appendix 56
Methodology 56
Ratio Definitions 56
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Lupin Ltd, Key Facts 6
Lupin Ltd, Key Employees 7
Lupin Ltd, Key Employee Biographies 8
Lupin Ltd, Major Products and Services 9
Lupin Ltd, Number of Pipeline Products by Therapy Area 10
Lupin Ltd, Number of Pipeline Products by Therapy Area (Cont...1) 11
Lupin Ltd, Number of Pipeline Products by Development Stage 12
Lupin Ltd, History 13
Lupin Ltd, Other Locations 20
Lupin Ltd, Subsidiaries 20
Lupin Ltd, Joint Venture 23
Lupin Ltd, Key Competitors 31
Lupin Ltd, Ratios based on current share price 32
Lupin Ltd, Annual Ratios 33
Lupin Ltd, Annual Ratios (Cont...1) 34
Lupin Ltd, Annual Ratios (Cont...2) 35
Lupin Ltd, Interim Ratios 37
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 39
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 40
Lupin Ltd, Recent Deals Summary 41
Currency Codes 56
Capital Market Ratios 56
Equity Ratios 57
Profitability Ratios 57
Cost Ratios 58
Liquidity Ratios 58
Leverage Ratios 59
Efficiency Ratios 59

List of Figures
Lupin Ltd, Pipeline Products by Therapy Area 10
Lupin Ltd, Pipeline Products by Development Phase 12
Lupin Ltd, Performance Chart (2012 - 2016) 36
Lupin Ltd, Ratio Charts 38
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 39
Lupin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 40

News

  • Understanding the Need For Travel Vaccination
  • If you are getting ready for a particular trip that can see you away from your house for about a month or so, then it is necessary for you to take the help of travel vaccinations. Not ...
  • The Work Of The Ophthalmology Specialist
  • When we consider ophthalmology as a branch of science, it is actually about the treatment as well as getting to diagnose the different kinds of diseases and the disorder that is to ...
  • The Process Of Dental Implants And The Subsequent Recovery
  • In the United States of America, the fear of going to a dentist happens to rank number one on the list of children as well as adults. Most of the people are actually concerned when ...
  • The medication that can help the rural population
  • It is not always that you get to see world class hospitals in the rural areas, be it America or any other country. Hence, it is important that people actually take the help of tele-medication, ...
  • The Future of Telemedicine & Its Use
  • When talking about telemedicine, you do get to realize that it is the healthcare of the future. Most of the people do not realize the implications, and for more so the time, telemedicine ...

Get Updates

Share This Post

Recent Posts

© 2017 RnR Company Profiles. All rights reserved.